Information  X 
Enter a valid email address

Indivior PLC (INDV)

  Print      Mail a friend

Thursday 04 April, 2019

Indivior PLC

Notice of Results

RNS Number : 0501V
Indivior PLC
04 April 2019


Indivior to Announce First Quarter 2019 Results on May 2nd and Host Conference Call


Slough, UK, and Richmond, VA, 4 April 2019 - Indivior PLC (LON: INDV) today announced that it will release its first quarter 2019 results on May 2nd at 12:00 BST (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the Company's website at


Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 13:00 BST (8:00 a.m. U.S. Eastern) on May 2nd.


Access the Live Webcast for the Results Call on May 2nd

The webcast event will be available on the "Investors" section of the Company's website at The webcast link is Participants also may access the results presentation telephonically: US participants 1-323-794-2149; international participants 44(0)330-336-9411. Please reference confirmation code 1140953. A replay of the presentation will be available at


About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit to learn more.



Jason Thompson

Vice President, Investor Relations

[email protected]



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t